Clinical Trials Browser

Prostatic Neoplasms × pembrolizumab × 1 year × Clear all

Prostatic Neoplasms

NCT07027124 2026-03-19

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Phase 2 Recruiting

40 enrolled

Genitourinary

Prostatic Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Phase 1/2 Recruiting

300 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04104893 2026-02-27

CHOMP

Phase 2 Active not recruiting

40 enrolled

Genitourinary

Turcot syndrome, Prostatic Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

240 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

83 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05787587 2026-02-09

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

216 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04946370 2026-02-03

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled

Genitourinary

Prostatic Neoplasms

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

Phase 2 Recruiting

64 enrolled

Genitourinary

Prostatic Neoplasms

NCT03007732 2025-12-05

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2 Completed

23 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT04090528 2025-12-05

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Phase 2 Active not recruiting

60 enrolled 10 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02312557 2025-12-03

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2 Active not recruiting

58 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT06400160 2025-11-25

Clinical Trial of TB511 in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

12 enrolled

GastrointestinalGenitourinary

Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03910660 2025-10-20

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

98 enrolled

EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1 Terminated

212 enrolled

Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05369000 2025-08-01

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Phase 1 Terminated

96 enrolled

Genitourinary

Prostatic Neoplasms

NCT07090369 2025-07-29

LumOnate

Phase 1 Not yet recruiting

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

Phase 3 Completed

1,030 enrolled 24 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04569461 2025-07-04

TALON

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02717156 2025-06-05

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Phase 2 Active not recruiting

103 enrolled

Genitourinary

Carcinoma, Transitional Cell, Prostatic Neoplasms

NCT04140526 2025-05-23

PRESERVE-001

Phase 1/2 Active not recruiting

733 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Clinical Trials

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

CHOMP

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

EBNK-ST-001

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Pembro With Radiation With or Without Olaparib

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Clinical Trial of TB511 in Advanced Solid Tumors

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

LumOnate

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

KEYNOTE-641

KEYNOTE-921

TALON

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

PRESERVE-001

KEYLYNK-010